Get started
Author

Lipsita Samantaray

Observed name: L. Samantaray
ORCID: 0009-0002-7909-6844
Observed ORCID: 0009-0002-7909-6844
OpenAlex ID: A5093018139
440P Low-dose nivolumab six weekly plus triple metronomic chemotherapy in advanced head and neck cancer: A prospective, open label single centre study from eastern India
2024 · S.K. Swain, L. Moharana, et al. · Annals of Oncology · 3
PDF
Navigating the complexity of BRAF mutations in non-small cell lung cancer: current insights and future prospects
2024 · Sufyan Ibrahim, Smita Shenoy, et al. · Multidisciplinary Respiratory Medicine · 3
PDF
Unveiling primary platinum resistant ovarian cancer: Demographic and clinical perspectives from multicenter cancer registry in India.
2024 · Lakhwinder Singh, Amit Sehrawat, et al. · Journal of Clinical Oncology · 2
PDF
Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India
2026 · Susheel Kumar Yeshala, Soumya Surath Panda, et al. · Journal of Ovarian Research · 1
PDF
71P Efficacy of low-dose nivolumab in advanced carcinomas
2024 · A. Tiwari, S.S. Panda, et al. · Annals of Oncology · 1
PDF
Six-Weekly Low-Dose Nivolumab Combined with Oral Triple Metronomic Chemotherapy for Advanced Cancers of the Head and Neck: An Open-Label, Prospective, Single-Institution Experience from Eastern India
2026 · Santosh Kumar Swain, Soumya Surath Panda, et al. · Research Square
PDF
Primary Leiomyosarcoma of the Urinary Bladder in a Middle-Aged Woman: A Case Report with Review of Previously Published Cases
2026 · Kartik Kadia, Lalatendu Moharana, et al. · Research Square
PDF
Clinicopathologic profile and comparative performance of limited next-generation sequencing and quantitative/real-time polymerase chain reaction for detection of RAS/RAF mutations in metastatic colorectal cancer
2026 · Ayush Dubey, Subhashree Subhasmita Dash, et al. · Research Square
PDF
Dual primary malignancies are no longer a rarity: A single centre experience from eastern India
2026 · Santosh Kumar Swain, Lalatendu Moharana, et al. · South Asian Journal of Cancer
PDF
Real-World Efficacy and Safety of Trastuzumab Emtansine Biosimilar (UJVIRA ® ) in Early and Metastatic HER2-Positive Breast Cancer: A Multicenter Pooled Retrospective Analysis from India
2026 · Ayesha Mahajan, Soumya Surath Panda, et al. · Research Square
179eP PARP inhibitor–associated therapy-related myeloid neoplasms in ovarian cancer: A multi-centre case series from Eastern India
2026 · L. Samantaray, S.K. Swain, et al. · ESMO Open
PDF
105eP Molecular profiling in endometrial carcinoma: Real-world evidence from an Indian cohort
2026 · I. Bhavya, S.S. Panda, et al. · ESMO Open
PDF
Clinicopathologic profile and comparative performance of limited next-generation sequencing and qPCR for detection of RAS/RAF mutations in stage IV colorectal cancer (mCRC).
2026 · Soumya Surath Panda, Ayush Dubey, et al. · Journal of Clinical Oncology
Primary Platinum-Resistant Ovarian Cancer: Clinicopathologic Correlates and Outcomes From a Multicenter Prospective Indian Registry
2026 · Amit Sehrawat, Lakhwinder Singh, et al. · JCO Global Oncology
27eP Real-world efficacy and safety of trastuzumab emtansine (T-DM1 Biosimilar, Ujvira) in early and metastatic HER2-positive breast cancer: A multicentre pooled retrospective analysis from India
2026 · S.S. Panda, A. Mahajan, et al. · ESMO Open
PDF
496eP Circulating interleukin gene expression and their impact on survival in ALK-rearranged advanced lung cancer
2026 · S. Meedimale, S.S. Panda, et al. · ESMO Open
Efficacy of Low-Dose Nivolumab in Advanced Carcinomas
2026 · Abhishek Tiwari, Soumya Surath Panda, et al. · Indian Journal of Medical and Paediatric Oncology
Low-Dose Nivolumab 6 Weekly Plus Triple Metronomic Chemotherapy in Advanced Head and Neck Cancer: A prospective, Open-Label Single-Center Study from Eastern India
2026 · Santosh Kumar Swain, Lalatendu Moharana, et al. · Indian Journal of Medical and Paediatric Oncology
127P Study of the profile of HER2-positive metastatic breast cancer patients receiving T-DM1 biosimilar, in a real-world setting
2025 · A. Mahajan, S.S. Panda, et al. · Annals of Oncology
634P Real-world evaluation of clinical outcome & feasibility of induction chemotherapy followed by concurrent chemoradiation in locally advanced cervical cancer at a tertiary centre
2025 · P.R. Sahoo, S.S. Panda, et al. · Annals of Oncology
689P NACT with DCF plus low-dose nivolumab in locally advanced technically unresectable oral cavity cancer: A single-centre study from eastern India
2025 · A.A. Bhange, L. Moharana, et al. · Annals of Oncology
534eP Response assessment of PSMA therapy in metastatic ca prostate: A single institutional experience from Eastern India
2025 · I. Bhavya, S.S. Panda, et al. · Annals of Oncology
363P HER-2 neu expression in gallbladder cancer: A real-world study on molecular alterations and targeted therapy response
2025 · R. Singhal, S.S. Panda, et al. · Annals of Oncology
PDF
362P Role of limited NGS in gallbladder cancer in LMIC: A real-world data of genomic profile and survival outcomes
2025 · R. Singhal, S.S. Panda, et al. · Annals of Oncology
Clinical and Survival Insights into Carcinoma Penis: A Retrospective Analysis at a Tertiary Care Facility
2025 · Santosh Kumar Swain, Lalatendu Moharana, et al. · South Asian Journal of Cancer
PDF
Works count: 32
Citation count: 10
H-index: 2
I10-index:
Year
Topic
Type